Latest News

(UroToday.com) Lutetium-177 is a radioligand that when bound to a prostate-specific membrane antigen (PSMA) targeting molecule delivers beta-particle radiation to PSMA-expressing cells and their local microenvironment. This therapy depends on prostate cancer cell surface expression of PSMA, which may be altered by androgen pathway inhibitors. To optimize the utility of this treatment modality in metastatic hormone-sensitive […]

(UroToday.com) Treatment options for men with metastatic castration resistant prostate cancer (mCRPC) are limited beyond taxane chemotherapy and second-generation androgen pathway inhibitors. Moreover, resistance to these agents is associated with the emergence of small cell neuroendocrine prostate cancer in a subset of patients (tSCNC), portending poor prognosis. Additional therapeutic options are required for patients who have […]

(UroToday.com) The advent of positron emission tomography using radiolabeled prostate-specific membrane antigen (PSMA) ligands, called PSMA-PET, is rapidly changing prostate cancer staging imaging. However, as all published randomized clinical trials and studies to date have utilized conventional imaging, the impact that PSMA-PET clinical upstaging should have on treatment is unknown. To address this question, the authors […]

(UroToday.com) The NIVOREN GETUF AFU 26 study is a French multi-center prospective study to evaluate the safety and efficacy of the anti-PD-1 checkpoint agent nivolumab in a “real world” setting after failure of 1-2 tyrosine kinase inhibitor in metastatic renal cell carcinoma (mRCC). As antibiotic use around the time of starting immune checkpoint blockade has […]

Profile: Prof. Evangelos Liatsikos, incoming Education Office chairman, hails strength and reputation of School   Prof. Evangelos Liatsikos (GR) has succeeded Prof. Joan Palou (ES) as chairman of the EAU’s Education Office following EAU21. We asked him about his previous experience and his plans for the European School of Urology in the coming years. Evangelos Liatsikos […]

(UroToday.com) VEGF-targeting therapies have been shown to induce hypoxia in preclinical models of renal cell carcinoma (RCC), thus activating signaling through the hypoxia-inducible factors. In this phase 2 study, Dr. McDermott and colleagues tested the hypothesis that dual inhibition of both VEGF and downstream HIF signaling would provide anti-tumor for patients with clear cell RCC.

Immunotherapy (anti-programmed death ligand 1 antibodies) is associated with improved survival rates in advanced kidney cell carcinoma (KCC) after progression on first-line tyrosine kinase inhibitor (TKI) treatment.

To review urinary protein biomarkers as potential non-invasive, easily obtainable, early diagnostic tools in renal cell carcinoma (RCC). A PubMed database search was performed up to the year 2020 to identify primary studies reporting potential urinary protein biomarkers for RCC.

Black men are more likely to die of prostate cancer (PCa) than White men. Whether this difference is driven by biological versus sociodemographic and access to care differences is actively investigated.

Artificial intelligence (AI) offers new opportunities for objective quantitative measurements of imaging biomarkers from positron-emission tomography/computed tomography (PET/CT). Clinical image reporting relies predominantly on observer-dependent visual assessment and easily accessible measures like SUVmax, representing lesion uptake in a relatively small amount of tissue.